Ultragenyx Pharmaceutical Inc

Most Recent

  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Ultragenyx Woos Investors with Good Returns in Mid-Cap Space

    Ultragenyx Pharmaceutical (RARE) rebounded on December 14, 2015, after falling for four consecutive days. The stock rose 3.8% and was the top performer among the mid-cap stocks that day.

    By Peter Neil
  • Company & Industry Overviews

    Discretionary Stocks Boost the Wells Fargo Growth Fund in YTD 2016

    Early 2016 was not generous to the Wells Fargo Growth Fund – Class A (SGRAX), and the fund was a below-average performer until May. However, things have improved since then.

    By David Ashworth
  • uploads///dna _
    Company & Industry Overviews

    PTC Therapeutics to Acquire Agilis Biotherapeutics

    On July 19, PTC Therapeutics (PTCT) agreed to acquire Agilis Biotherapeutics. The acquisition is expected to close during Q3 2018.

    By Daniel Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    Can XBI Continue the Upward Trend It Achieved in May?

    The SPDR S&P Biotech ETF (XBI) reflected the performance of SPY and rose 0.2%, continuing its upward trend. XBI had a good month in May and began June on a positive note.

    By Peter Neil
  • Company & Industry Overviews

    How the Consumer Discretionary Sector Has Affected SGRAX in 2016

    The Wells Fargo Growth Fund Class A (SGRAX) had fallen by 1% year-to-date (or YTD) in 2016 as of May 27, 2016.

    By David Ashworth
  • uploads///Part  Graph
    Company & Industry Overviews

    IBB’s Mid-Cap Stocks: Kite Pharma Drug Gets Orphan Drug Status

    IBB’s mid-cap holding Kite Pharma (KITE) rose by 3.3% on the news of the FDA granting orphan drug status to Kite’s KTE-C19.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Mid-Cap Stock Update: Horizon Tanks 21% on Earnings Concerns

    In the mid-cap space, Horizon Pharma (HZNP) was the worst hit, falling by 21% for the week ended April 15, 2016.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI News as of March 16: Mid-Caps Under Pressure

    Given selling pressures, XBI’s 18 mid-cap stocks went down marginally on average, losing 0.4% on March 16. Eight stocks advanced while ten stocks declined.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Moving Averages of XBI’s Holdings Have Improved

    The moving averages of the stocks in the SPDR S&P Biotech ETF (XBI) have seen drastic improvements recently.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Shire-Dyax Merger Drove Biotech Stocks

    Shire (SHPG) announced that it will acquire Dyax (DYAX) for $37.30 per Dyax share in a deal valued at ~$5.9 billion.

    By Peter Neil
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Ultragenyx: A Top Loser in the Biotechnology Subgroup

    Ultragenyx Pharmaceutical (RARE) fell by 8.2% due to profit-booking. It had a high trading volume of ~700,000 shares. The stock closed at $86.99.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.